Adenovirus provides many opportunities as a vector for delivery of cytotoxic genes to tumours. Polymer coating of adenovirus is known to increase its plasma circulation kinetics, affording the possibility of active and passive targeting to tumours. Here we show that polymer-coating adenovirus (pc-virus) abrogates its normal infectivity in vitro and also in liver following intravenous injection. The coated virus accumulates within solid subcutaneous AB22 mesothelioma tumours 40-times more than unmodified virus, and mediates higher levels of transgene expression within tumours. This is the first demonstration of passive tumour targeting of polymer-coated adenoviruses administered by intravenous injection, and also the first time pc-virus has ...
BACKGROUND: Oncolytic viruses are among the most powerful and selective cancer therapeutics under de...
Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intra...
AbstractClinical experience with adenovirus vectors has highlighted the need for improved delivery a...
Intravenous delivery of therapeutic virus particles remains a major goal for virotherapy of metastat...
Adenovirus is a widely used vector for cancer gene therapy because of its high infection efficiency ...
Adenovirus gene therapy for intraperitoneal (IP) cancer is limited in clinical trials by inefficient...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
BACKGROUND: Transductional targeting of adenovirus following systemic or regional delivery remains o...
ABSTRACT: Adenovirus (Ad) vectors show promise as cancer gene therapy delivery vehicles, but immunog...
Oncolytic adenoviruses (Ad) that selectively replicate in cancer cells are emerging as a promising n...
Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials...
Background Oncolytic adenovirus (Ad)-mediated gene therapy is a promising approach for suppression o...
Clinical experience with adenovirus vectors has highlighted the need for improved delivery and targe...
Adenoviral vectors offer many advantages for cancer gene therapy, including high transduction effici...
Clinical experience with adenovirus vectors has highlighted the need for improved delivery and targe...
BACKGROUND: Oncolytic viruses are among the most powerful and selective cancer therapeutics under de...
Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intra...
AbstractClinical experience with adenovirus vectors has highlighted the need for improved delivery a...
Intravenous delivery of therapeutic virus particles remains a major goal for virotherapy of metastat...
Adenovirus is a widely used vector for cancer gene therapy because of its high infection efficiency ...
Adenovirus gene therapy for intraperitoneal (IP) cancer is limited in clinical trials by inefficient...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
BACKGROUND: Transductional targeting of adenovirus following systemic or regional delivery remains o...
ABSTRACT: Adenovirus (Ad) vectors show promise as cancer gene therapy delivery vehicles, but immunog...
Oncolytic adenoviruses (Ad) that selectively replicate in cancer cells are emerging as a promising n...
Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials...
Background Oncolytic adenovirus (Ad)-mediated gene therapy is a promising approach for suppression o...
Clinical experience with adenovirus vectors has highlighted the need for improved delivery and targe...
Adenoviral vectors offer many advantages for cancer gene therapy, including high transduction effici...
Clinical experience with adenovirus vectors has highlighted the need for improved delivery and targe...
BACKGROUND: Oncolytic viruses are among the most powerful and selective cancer therapeutics under de...
Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intra...
AbstractClinical experience with adenovirus vectors has highlighted the need for improved delivery a...